NZ561900A - Crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide - Google Patents

Crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide

Info

Publication number
NZ561900A
NZ561900A NZ561900A NZ56190006A NZ561900A NZ 561900 A NZ561900 A NZ 561900A NZ 561900 A NZ561900 A NZ 561900A NZ 56190006 A NZ56190006 A NZ 56190006A NZ 561900 A NZ561900 A NZ 561900A
Authority
NZ
New Zealand
Prior art keywords
crystalline
salt form
crystalline salt
oxo
amino
Prior art date
Application number
NZ561900A
Other languages
English (en)
Inventor
Paul R Fatheree
S Derek Turner
Adam Goldblum
Robert Chao
Daniel Genov
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of NZ561900A publication Critical patent/NZ561900A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ561900A 2005-04-06 2006-04-05 Crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide NZ561900A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06
PCT/US2006/012978 WO2006108127A2 (en) 2005-04-06 2006-04-05 Crystalline form of a quinolinone-carboxamide compound

Publications (1)

Publication Number Publication Date
NZ561900A true NZ561900A (en) 2010-12-24

Family

ID=37074104

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ561900A NZ561900A (en) 2005-04-06 2006-04-05 Crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide

Country Status (29)

Country Link
US (4) US7728004B2 (OSRAM)
EP (1) EP1874766B1 (OSRAM)
JP (2) JP5230407B2 (OSRAM)
KR (1) KR101322873B1 (OSRAM)
CN (1) CN101151264B (OSRAM)
AR (2) AR053208A1 (OSRAM)
AT (1) ATE479682T1 (OSRAM)
AU (1) AU2006232129B2 (OSRAM)
BR (1) BRPI0610657A2 (OSRAM)
CA (1) CA2603654C (OSRAM)
CY (1) CY1111275T1 (OSRAM)
DE (1) DE602006016586D1 (OSRAM)
DK (1) DK1874766T3 (OSRAM)
EA (1) EA012115B1 (OSRAM)
ES (1) ES2350495T3 (OSRAM)
HR (1) HRP20100629T1 (OSRAM)
IL (1) IL186023A (OSRAM)
MA (1) MA29403B1 (OSRAM)
MX (1) MX2007012438A (OSRAM)
MY (1) MY151075A (OSRAM)
NO (1) NO339699B1 (OSRAM)
NZ (1) NZ561900A (OSRAM)
PE (1) PE20061310A1 (OSRAM)
PL (1) PL1874766T3 (OSRAM)
PT (1) PT1874766E (OSRAM)
SI (1) SI1874766T1 (OSRAM)
TW (1) TWI377206B (OSRAM)
WO (1) WO2006108127A2 (OSRAM)
ZA (1) ZA200708071B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
ATE431824T1 (de) 2004-11-05 2009-06-15 Theravance Inc Chinolinon-carboxamid-verbindungen
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
US20080287486A1 (en) * 2007-05-17 2008-11-20 Theravance, Inc. Prokinetic agent for bowel preparation
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
NZ614151A (en) * 2007-12-07 2015-04-24 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
HUE038141T2 (hu) * 2009-04-13 2018-10-29 Theravance Biopharma R&D Ip Llc 5-HT4 receptor agonisták és acetilkolinészteráz inhibitorok kombinációi kognitív rendellenességek kezelésére
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
ES3017582T3 (en) 2010-04-07 2025-05-13 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
CN105848657B (zh) 2013-11-12 2020-05-22 沃泰克斯药物股份有限公司 制备用于治疗cftr介导的疾病的药物组合物的方法
SI3661518T1 (sl) * 2017-07-31 2025-01-31 Alfasigma S.P.A. Načini zdravljenja simptomov gastropareze z zdravilom velusetrag
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
JP2025533507A (ja) 2022-09-20 2025-10-07 アルファシグマ ソシエタ ペル アチオニ 慢性偽性腸閉塞症（ｃｉｐｏ）の治療に使用するためのベルセトラグ

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
CA2097815C (en) 1990-12-28 2001-04-17 Fumio Suzuki Quinoline derivative
EP0670319A4 (en) 1992-11-20 1996-01-17 Thaisho Pharmaceutical Co Ltd HETEROCYCLIC COMPOUNDS.
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
WO2005049608A1 (en) 2003-11-24 2005-06-02 Pfizer Japan, Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
ATE441646T1 (de) 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
ATE431824T1 (de) 2004-11-05 2009-06-15 Theravance Inc Chinolinon-carboxamid-verbindungen
JP2008530225A (ja) 2005-02-17 2008-08-07 セラヴァンス， インコーポレーテッド インダゾール−カルボキサミド化合物の結晶型
WO2006094063A1 (en) 2005-03-02 2006-09-08 Theravance, Inc. Quinolinone compounds as 5-ht4 receptor agonists
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Also Published As

Publication number Publication date
NO20075574L (no) 2007-11-02
KR101322873B1 (ko) 2013-10-30
HRP20100629T1 (hr) 2010-12-31
PT1874766E (pt) 2010-11-30
JP5230407B2 (ja) 2013-07-10
BRPI0610657A2 (pt) 2010-07-13
CN101151264A (zh) 2008-03-26
EA200702161A1 (ru) 2008-04-28
EP1874766A2 (en) 2008-01-09
IL186023A (en) 2011-09-27
PL1874766T3 (pl) 2011-02-28
EA012115B1 (ru) 2009-08-28
MA29403B1 (fr) 2008-04-01
EP1874766B1 (en) 2010-09-01
AR110019A2 (es) 2019-02-13
JP2012153725A (ja) 2012-08-16
IL186023A0 (en) 2008-01-20
TW200643020A (en) 2006-12-16
CA2603654A1 (en) 2006-10-12
ATE479682T1 (de) 2010-09-15
AU2006232129A1 (en) 2006-10-12
WO2006108127A3 (en) 2007-01-04
DE602006016586D1 (de) 2010-10-14
PE20061310A1 (es) 2007-01-23
US7728004B2 (en) 2010-06-01
US20160095849A1 (en) 2016-04-07
HK1110866A1 (en) 2008-07-25
US20100197728A1 (en) 2010-08-05
CA2603654C (en) 2014-05-27
US20140256769A1 (en) 2014-09-11
US9126994B2 (en) 2015-09-08
NO339699B1 (no) 2017-01-23
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
AR053208A1 (es) 2007-04-25
WO2006108127A2 (en) 2006-10-12
TWI377206B (en) 2012-11-21
CN101151264B (zh) 2011-07-06
ZA200708071B (en) 2008-10-29
AU2006232129B2 (en) 2012-07-12
US20060229332A1 (en) 2006-10-12
CY1111275T1 (el) 2015-08-05
KR20070116988A (ko) 2007-12-11
DK1874766T3 (da) 2010-12-06
JP2008535848A (ja) 2008-09-04
SI1874766T1 (sl) 2010-12-31
ES2350495T3 (es) 2011-01-24
MY151075A (en) 2014-03-31
MX2007012438A (es) 2007-12-05

Similar Documents

Publication Publication Date Title
US9402840B2 (en) Crystalline form of a quinolinone-carboxamide compound
EP1735304B1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
EP1807423B1 (en) Quinolinone-carboxamide compounds
WO2005080389A1 (en) Indazole-carboxamide compounds as 5-ht4 receptor agonists
EP1902053B1 (en) Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists
US8288550B2 (en) Crystalline form of a benzimidazole-carboxamide medicinal compound
US20060183901A1 (en) Crystalline form of an indazole-carboxamide compound
EP1871772A1 (en) Quinolinone compounds as 5-ht4 receptor agonists
EP1960396B1 (en) Carbamate compounds as 5-ht4 receptor agonists
HK1110866B (en) Crystalline form of a quinolinone-carboxamide compound
HK1099019B (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 APR 2016 BY COMPUTER PACKAGES INC

Effective date: 20130426

ASS Change of ownership

Owner name: THERAVANCE BIOPHARMA R+D IP, LLC, US

Effective date: 20140807

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 APR 2017 BY COMPUTER PACKAGES INC

Effective date: 20160318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 APR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 APR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180320

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 APR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190319

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 APR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 APR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 APR 2023 BY COMPUTER PACKAGES INC

Effective date: 20220317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 APR 2024 BY CPA GLOBAL

Effective date: 20230216

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 APR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240223

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 APR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250227

ASS Change of ownership

Owner name: ALFASIGMA S.P.A., IT

Effective date: 20250305